These include RNA interference techniques, such as small interfering RNAs (siRNAs) and antisense oligonucleotides (ASOs), designed to downregulate oncogenic lncRNAs; restoration of tumor-suppressive lncRNAs to re-establish negative regulation of TGFβ signaling; and the use of small-molecule inhibitors or monoclonal antibodies to block TGFβ receptors or interfere with SMAD-mediated transcriptional activation. This evidence concerns the gene TGFB1 and neoplasm.